Abstract: The invention provides heterocyclic guanidine compounds that inhibit F1F0-ATPase, and methods of using heterocyclic guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
Type:
Grant
Filed:
June 7, 2013
Date of Patent:
December 29, 2015
Assignee:
Lycera Corporation
Inventors:
Alexander R. Hurd, Clarke B. Taylor, Peter L. Toogood